Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Acumen Pharmaceuticals Presents Sabirnetug Fluid Biomarker, Target Engagement Analyses From Phase 1 INTERCEPT-AD Study In Early Alzheimer's At AD/PD 2024 Annual Meeting

Author: Benzinga Newsdesk | March 08, 2024 09:57am

Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD

 

- Poster presentation showcases method used to develop a first-of-its-kind assay to assess sabirnetug's binding to amyloid beta oligomers (AβOs) in Alzheimer's disease

 

- Company on track to initiate Phase 2 trial evaluating sabirnetug in the first half of 2024 and Phase 1 subcutaneous study in mid-2024

Posted In: ABOS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist